Skip to main content

Table 2 Grading of toxicity during the 4 cycles in the two studied groups

From: Intermittent fasting during adjuvant chemotherapy may promote differential stress resistance in breast cancer patients

Toxicity Intermittent fasting
(n = 24)
Non-fasting (n = 24) P
Grade 1
No. %
Grade 2
No. %
Grade 3
No. %
Grade 1
No. %
Grade 2
No. %
Grade 3
No. %
Thrombocytosis 6 (25%) - - 7 (29.167%) 1 (4.167%) 0.525
Neutropenia 2 (8.33%) 2 (8.33%) - - 2 (8.33%) 1 (4.17%) FEp = 1.000
Headache 7 (29.17%) 2 (8.33%) - 5 (20.83%) 1 (4.167%) 0.350
Mouth sores - - - 5 (20.83%) 3 (12.5%) FEp = 0.004**
Diarrhea - - - 9 (37.5%) 3 (12.5%)  < 0.001***
Constipation 6 (25%) 2 (8.33%) - - - FEp = 0.004**
Vomiting 2 (8.33%) - - 14 (58.3%) 5 (20.83%)  < 0.001***
Nausea 16 (66.67%) 1 (4.17%) - 19 (79.16%) 5 (20.83%) FEp = 0.009**
Hair loss 12 (50%) 6 (25%) - 19 (79.16%) 4 (16.67%) FEp = 0.188
Fatigue 6 (25%) 3 (12.5%) - 11 (45.83%) 2 (8.33%) 0.247
  1. FE Fisher exact. P P-value for comparing between intermittent fasting and non-fasting group
  2. *P < 0.05
  3. **P < 0.01
  4. ***P < 0.001